A Review on In Situ Gelling System for Ophthalmic Drug Delivery
Abstract
Ophthalmic drug delivery systems are both fascinating and problematic due to the normal physiological properties of the eyes, which restrict ocular product bioavailability. The development of novel ocular dosage forms for current drugs in order to enhance efficacy and bioavailability, as well as patient compliance and convenience, has become a major focus in the pharmaceutical business. Ocular In-situ gelling systems are a novel type of eye drug delivery systems that begin as a solution but rapidly convert into a thick gel when implanted or inserted into an ocular cavity where active pharmaceuticals are continually delivered. This sol-to-gel phase conversion is influenced by a range of variables, including variations in pH, the presence of ions, and temperature fluctuations. Post-transplantation gel is chosen for its viscosity and bio adhesive qualities, which prolongs the gel's presence in the ocular area and also ensures that the medicine is released slowly and continuously, in contrast to typical eye drops and ointments. This article provides an overview of situ gels, their numerous techniques of gelling, the many types of polymers utilized in situ gels, their gel-based methodologies, and the polymeric testing of situ gels.
References
2. Parashar AK, Patel P, Gupta A, Jain N, Kurmi B. Synthesis Characterization and in vivo Evaluation of PEGylated PPI Dendrimer for Safe and Prolonged Delivery of Insulin.Drug Del Letters. 2019; 9: 248-63.
3. Gurtler F, Gurny R. Patent literature review of ophthalmic inserts. Drug Dev Ind Pharma. 1995; 21: 1-8.
4. Rathore R, Gupta AK, Parashar AK. Formulation and Evaluation of fast dissolving films of Granisetron Hydrochloride. J Drug Delivery and Therapeutics. 2019; 9(2-A):36-38.
5. Tortora GJ and Grabowski SR. Principles of Anatomy and physiology, Harper Collins College publishers, 7th edition. 1993; 474-476.
6. Sasaki H, Yamamura K, Mukai T, Nishida k, Nakamura J, Nakashima M. Enhancement of ocular drug penetration. Crit Rev Drug Carrier Syst. 1999; 16: 85-146.Parashar AK, Kakde D, Chadhar V, Devaliya R, Shrivastav V, Jain UK. A review on solid lipid nanoparticles (SLN) for controlled and targeted delivery of medicinal agents. Curr Res Pharm Sci. 2011; 1(2): 37-47.
7. Parashar AK, Kurmi B, Patel P. Preparation and characterization of ligand anchored polymeric nanoparticles for the treatment of epilepsy. Pharmaspire. 2021; 13(1):1-5.
8. Worakul N, Robinson JR. Ocular pharmacokinetics/pharmacodynamics. Eur J Pharma Bipharm. 1997; 44: 71-83.
9. Aparna VB, Sitansh S. In-situ gelling ophthalmic drug delivery system for glaucoma. IJPBS.2011; 2(2):7-17.
10. Urtti. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 2006; (58):1131–1135.
11. Parashar AK, Nema RK. Preparation and Characterization of Polymeric Nanoparticles for Sustained Delivery of Insulin. Curr Res Pharm Sci.2012; 153-159.
12. Bhaskaran S, Lakshmi PK, Harish CG. Topical ocular drug delivery a review. Ind. J.Pharm. Sci. 2005;67(4):404–408.
13. Mohd, Aqil. Advances in ophthalmic drug delivery system: par I 2005; Hamdard University, New Delhi. 123-125.
14. Annick Ludwig. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57:1595–1639.
15. Gokulgandhi, Dharmesh, Modi M, Jolly RP. Ocular delivery in-situ gel systems for ocular drug delivery: A review. Drug delivery technology. 2007;7:3.
16. Ali Y, Lehmussaari K. Industrial perspective in ocular delivery. Adv Drug Deliv Rew. 2006; 58: 1258-1268.
17. El-Emam GA, Girgis GNS, El-Sokkary MMA, El-Azeem Soliman OA, Abd El Gawad AEGH. Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies. Int J Nanomedicine. 2020;15:7825-7840.
18. Nagpal MA, Sharma K, Anand N, Singh D, Dhawan R, Usman MRM, Nagpal N. Preparation and Evaluation of Sulfacetamide Sodium Ocusert for Controlled Drug Delivery. JDDT, 2020;10(2):164-70.
19. Sandeep DS, Charyulu RN and Dubey A: Sustained release ophthalmic in-situ gels of dorzolamide HCl for glaucoma-an approach to formulation and in-vitro evaluation. Int J Pharm Sci & Res 2020; 11(12): 6425-33
20. Guven Umay Merve, Berkman Murat Sami, Şenel Behiye, Yazan Yasemin. Development and in vitro/in vivo evaluation of thermo-sensitive in situ gelling systems for ocular allergy. Braz. J. Pharm. Sci. 2019; 55: e17511.
21. Sharma A, Pahwa S, Bhati S, Kudeshia P. Formulation and evaluation of dorzolamide spanlastics. IJPSR.2019, 0975-8232.
22. Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Recent advances in ocular drug delivery. Drug Development and Industrial Pharmacy. 2012; 39(11):1-19.https://doi.org/10.3109/03639045.2012.73651525.
23. Wei G, Xu H, Ding PT, Li S M, Zheng J M J, Thermosetting Gels With Modulated Gelation Temperature For Ophthalmic Use. The Rheological and Gamma Scintigraphic Studies. J Controlled Rel. 2002; 83:64-65.https://doi.org/10.1016/S0168-3659(02)00175-X27.
24. Chhetri P, Chakraborty P, Das D, Afnan T. In-situ forming polymeric drug delivery systems for opthalamic use: An overeview. Journal of Drug Delivery and Therapeutic. 2021; 11(3-s):98-103.https://doi.org/10.22270/jddt.v11i3-S.487429.
25. Aishwarya JJ, Sheetal BG, Ravindra BS. A review on nasal drug delivery system. World J Pharmacy and Pharm. Sci 2014; 3:231-54.30. Prajapati N, Goyal A. A review: thermoreversible mucoadhesive in-situ gel. Int J Innovative Drug Discovery. 2013; 3:67-84.31.
26. Kavitha K, Santosh KP, M Rup, Jagadeesh S, et al. Recent development and strategies of ocular Insitu drug delivery system: A review. International Journal of Pharmaceutical and Clinical Research. 2013; 5(2):64-71.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.